Work

Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced ovarian cancer

Year: 2011

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2010.12.159

Authors: J. Lesnock, C. Farris, T. Krivak, K. Smith, M. Markman

Institutions: Magee-Womens Hospital, University of Pittsburgh, Cancer Treatment Centers of America, Eastern Regional Medical Center

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4253967357

FWCI:

Cites:

Cited by: 1

Related to: 10